Skip to main content

Table 4 Effects of TNF-α inhibitor treatment on lipid profile: stratification analysis by statin use

From: Effects of anti-TNF-α treatment on lipid profile in rheumatic diseases: an analytical cohort study

  

No statins

Statin treatment begun after initiating TNF-α inhibitor treatment

Statin treatment begun before and continued during TNF-α inhibitor treatment

 

Time period

Mean ± standard error

p value

Mean ± standard error

p value

Mean ± standard error

p value

Total cholesterola (mg/dl)

Reference

183.73 ± 3.26

 

188.96 ± 8.92

 

182.04 ± 5.65

 

0–6 months

188.63 ± 3.42

0.007

208.22 ± 9.02

0.005

188.78 ± 5.73

NS

6–12 months

185.20 ± 3.29

NS

197.92 ± 8.74

NS

184.05 ± 5.60

NS

12–18 months

187.77 ± 3.22

0.03

198.55 ± 9.15

0.04

180.42 ± 5.48

NS

18–24 months

188.62 ± 3.34

NS

199.38 ± 8.46

0.01

178.89 ± 5.14

NS

LDLa (mg/dl)

Reference

103.13 ± 3.68

 

112.10 ± 5.62

 

119.97 ± 2.86

 

0–6 months

106.01 ± 3.83

0.057

123.42 ± 7.62

0.05

107.84 ± 3.96

<0.001

6–12 months

105.63 ± 3.80

NS

115.35 ± 7.05

NS

108.26 ± 4.07

<0.001

12–18 months

106.85 ± 3.80

0.02

119.67 ± 6.38

0.03

101.85 ± 3.57

<0.001

18–24 months

107.70 ± 3.76

0.001

115.89 ± 6.81

NS

104.02 ± 3.57

<0.001

Triglyceridesa (mg/dl)

Reference

119.41 ± 9.75

 

179.31 ± 19.96

 

142.14 ± 9.89

 

0–6 months

134.33 ± 10.24

<0.001

223.91 ± 24.84

0.002

147.33 ± 10.67

NS

6–12 months

128.80 ± 10.05

0.02

186.09 ± 20.47

NS

145.81 ± 10.15

NS

12–18 months

135.89 ± 10.19

0.001

181.31 ± 20.98

NS

149.60 ± 10.16

NS

18–24 months

135.99 ± 10.20

<0.001

194.68 ± 23.42

NS

146.72 ± 10.82

NS

  1. aAdjusted for hyperlipidemia, hypertension, obesity, gender, and age
  2. TNF-α tumor necrosis factor alpha, LDL low-density lipoprotein, NS not significant